Curated CRC research — accessible, accurate, actionable

The CRC Digest

Wednesday, September 02, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ RESEARCH

  Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

  While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common KRAS mutations in CRC. (J Gastrointest Cancer)

• ♥ LIVING WITH CRC

  Case series from Tanzania documents colorectal cancer in patients under 30

  Three patients under age 30 presented with advanced disease after prolonged symptoms including rectal bleeding and weight loss; two had mucinous adenocarcinoma and one had a family history suggesting hereditary risk. (J Surg Case Rep)

• ▪ SCREENING

  AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore

  Computer-assisted detection (CADe) during screening colonoscopy improves adenoma detection rates while reducing endoscopists' mental fatigue. (Int J Surg)

• ◇ RESEARCH

  Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC

  Researchers used single-cell RNA sequencing to compare PD-1-resistant and PD-1-sensitive MSI-H metastatic colorectal tumors, identifying a gene regulatory network involving ETV4 and MC1R that may explain why some MSI-H cancers don't respond to immunotherapy. (Int J Surg)

• ◇ RESEARCH

  Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients

  A prospective multicenter registry enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six Moscow centers between 2022 and 2025 to establish population-level data on mismatch repair deficiency prevalence and clinical correlates. (Front Oncol)

Research continues to refine our understanding of treatment resistance and expand options for hard-to-treat mutations.